Echoing concerns expressed by oncologists early in the COVID-19 pandemic, a study led by researchers from Imperial College London (London, UK) has reported that the survival of patients with cancer after infection with SARS-CoV-2 seems to be disparate between the UK and countries in continental Europe, with apparently more detrimental outcomes for patients in the UK compared with their European…
The burden of cancer is projected to rise exponentially in many parts of the world and represents an impending global health crisis unless we act…
A draft bill to allow medically assisted dying for patients with incurable conditions will be debated by the National Assembly in France on May 27,…
In March, 2024, an Advisory Group of 28 independent scientists from 22 countries met in Lyon, France to recommend priorities for carcinogenicity evaluations by the…
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk…
People with cancer have a higher risk of mortality from COVID-19 than those without cancer. Patients younger than 50 years with cancer treatment have the…
In March, 2024, an Advisory Group of 28 independent scientists from 22 countries met in Lyon, France to recommend priorities for carcinogenicity evaluations by the…
Cabozantinib in advanced adrenocortical carcinoma showed promising efficacy with a manageable and anticipated safety profile. Further prospective studies with cabozantinib alone and in combination with…
Cabozantinib shows promising activity in patients with MPPGs.
